Opens in a new tab or window “Compared to non-CMR recipients, CMR recipients experienced a considerably higher increase in adherence to COPD medications from 2016 to 2017, and findings with data ...

Since this is a progressive disease, having a COPD treatment plan is key to breathing easier in the long term. COPD is a lung condition that restricts airflow, making breathing more difficult.

Dupixent is an “add-on” drug for COPD, meaning patients take it in addition to inhaled medication Dupixent isn’t approved as a stand-alone treatment for COPD. The U.S. Food and Drug ...

Study objectives: To identify the predictors of medication adherence in patients with COPD and contrast the health beliefs, experiences, and behaviors of COPD patients self-reporting good ...

3/4 inhibitor – now given the somewhat tongue-twisting brand name of Ohtuvayre – is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD ...

Currently, COPD-marketed therapy leaders include GSK’s Trelegy Ellipta, which is set to grow in sales to $2.16bn by 2033.

Smoking is the most common aetiologic factor. Evidence for the treatment of patients with mild-to-moderate COPD is limited. Here, the authors show that long-term treatment with high-dose N ...

Regeneron and Sanofi on Friday said the green light covers Dupixent as an add-on maintenance treatment in certain adults with uncontrolled chronic obstructive pulmonary disease, or COPD ...

[39,40,41,42,43,44,45] Significant differences in health beliefs, experiences, and behaviors were observed between COPD patients with high medication adherence and suboptimal adherence. The ...

Ahmedabad (Gujarat) [India], October 16: Jayeshkumar Jani, 61, faced overwhelming health challenges due to severe obesity.